nach oben

Erschienen in:

2018 | OriginalPaper | Buchkapitel

5. Ersttrimesterscreening

verfasst von : Prof. Dr. med. MHBA K.-O. Kagan, PD Dr. med. H. Abele, Prof. Dr. med. M. Hoopmann

Erschienen in: Ultraschalldiagnostik in Geburtshilfe und Gynäkologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Ersttrimesterscreening hat sich in den vergangenen Jahren dramatisch verändert. War es zu Beginn nur als Screeningtest für Trisomie 21 gedacht, ist es heute eine umfassende Risikoanalyse für zahlreiche Komplikationen in der Schwangerschaft. So können heute im Rahmen des Ersttrimesterscreenings etwa die Hälfte aller Fehlbildungen erkannt und die Risiken für Präeklampsie, Frühgeburt und zahlreiche weitere Schwangerschaftskomplikationen ermittelt werden. Das eigentliche kombinierte Screening auf Trisomie 21 basierend auf dem mütterlichem Altersrisiko, der fetalen Nackentransparenz und den Serummarkern freies beta-hCG und PAPP-A rückt dabei in den Hintergrund und wurde in den vergangenen Jahren zunehmend durch die zellfreie DNA-Analyse aus dem mütterlichen Blut abgelöst.

Vorheriges Kapitel Ersttrimesterultraschall

Nächstes Kapitel Gehirn und Wirbelsäule

Abele H, Wagner N, Hoopmann M, Grischke EM, Wallwiener D, Kagan KO (2010) Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol 35: 525–529

Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31: 66–74

Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH (2013) Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33: 8–15

Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F (2015) Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 45: 16–26

Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH (2013) Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 41: 26–32

Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH (2005) Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 26: 154–157

Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11–13 weeks. Prenat Diagn 31: 75–83

Bilardo CM, Muller MA, Pajkrt E, Clur SA, van Zalen M, Bijlsma EK (2007) Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 30: 11–18

Bilardo CM, Timmerman E, Pajkrt E, van Maarle M (2010) Increased nuchal translucency in euploid fetuses – what should we be telling the parents? Prenat Diagn 30: 93–102

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116: 402–414

Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH (2011) Contribution of ductus venosus Doppler in first-trimester screening for major cardiac defects. Fetal Diagn Ther 29: 127–134

Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH (2006) Nasal bone in first–trimester screening for trisomy 21. Am J Obstet Gynecol 195: 109–114

Cuckle HS (2011) Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 32 (Suppl): S42–S48

Cuckle HS, Wald NJ, Thompson SG (1987) Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387–402

Cuckle H, Benn P, Wright D (2005) Down syndrome screening in the first and/ or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 29: 252–257

De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A (2012) Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 307: 2286–2294

De Souza E, Halliday J, Chan A, Bower C, Morris JK (2009) Recurrence risks for trisomies 13, 18 and 21. Am J Med Genet A 149: 2716–2722

Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337: a2547

Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH (2011) Maternal serum visfatin at 11–13 weeks of gestation in gestational diabetes mellitus. Clin Chem 57: 609–613

Flenady V, Koopmans L, Middleton P, Frøen JF, Smith GC, Gibbons K, Coory M, Gordon A, Ellwood D, McIntyre HD, Fretts R, Ezzati M (2011) Major risk factors for stillbirth in high-income countries: a systematic review and metaanalysis. Lancet 377: 1331–1340

Fuchs IB, Muller H, Abdul-Khaliq H, Harder T, Dudenhausen JW, Henrich W (2007) Immediate and long-term outcomes in children with prenatal diagnosis of selected isolated congenital heart defects. Ultrasound Obstet Gynecol 29: 38–43

Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH (2017) Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol doi: 10.1002/uog.17484. [Epub ahead of print]

Greco E, Lange A, Ushakov F, Calvo JR, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks. Prenat Diagn 31: 84–89

Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study. BMJ 318: 81–85

Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH (2006) Relation between increased fetal nuchal translucency, thickness and chromosomal defects. Obstet Gynecol 107: 6–10

Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH (2007) Discordance in nuchal translucency, thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 29: 527–532

Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH (2008a) Screening for trisomy 21 by maternal age fetal nuchal translucency thickness free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 31: 618–624

Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008b) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493–502

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH (2008c) Screening for trisomies 21 18 and 13 by maternal age fetal nuchal translucency fetal heart rate free beta-HCG and pregnancy-associated plasma protein-A. Hum Reprod 23: 1968–1975

Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH (2009a) Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33: 259–264

Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009b) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34: 14–18

Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH (2009c) Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 33: 18–22

Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH (2009d) Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 33: 657–664

Kagan KO, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH (2010) The 11–13- week scan: diagnosis and outcome of holoprosencephaly exomphalos and megacystis. Ultrasound Obstet Gynecol 36: 10–14

Kagan KO, Eiben B, Kozlowski P (2014) Kombiniertes Ersttrimesterscreening und zellfreie fetale DNA – »Next Generation Screening«. Ultraschall Med 35: 229–236

Kagan KO, Schmid M, Hoopmann M, Wagner P, Abele H (2015a) Screening performance and costs of different strategies in prenatal screening for trisomy 21. Geburtsh Frauenheilk 75: 244–250

Kagan KO, Wright D, Nicolaides KH (2015b) First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 45: 42–47

Lau TK, Cheung SW, Lo PSS, Pursley AN, Chan MK, Jiang F, Zhang H, Wang W, Jong LFJ, Yuen OKC, Chan HYC, Chan WSK, Choy KW (2014) Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. Ultrasound Obstet Gynecol 43: 254–264

Lo YM, Corbetta N, Chamberlain PF, Redman CW, Sargent IL, Rai V, et al (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350: 485–487

Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K (2011) A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 37: 38–47

Maiz N, Kagan KO, Milovanovic Z, Celik E, Nicolaides KH (2008) Learning curve for Doppler assessment of ductus venosus flow at 11 + 0 to 13 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 31: 503–506

Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH (2009) Ductus venosus Doppler in screening for trisomies 21,18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33: 512–517

Maiz N, Wright D, Ferreira AFA, Syngelaki A, Nicolaides KH (2012) A Mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11–13 weeks gestation. Fetal Diagn Ther 31: 221–229

Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D’Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium (2005) First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 353: 2001–2011

Matias A, Montenegro N, Loureiro T, Cunha M, Duarte S, Freitas D, Severo M (2010) Screening for twin-twin transfusion syndrome at 11–14 weeks of pregnancy: the key role of ductus venosus blood flow assessment. Ultrasound Obstet Gynecol 35: 142–148

Merz E, Thode C, Alkier A, Eiben B, Hackelöer BJ, Hansmann M, Huesgen G, Kozlowski P, Pruggmaier M, Wellek S (2008) A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in der Medizin 29: 639–645

Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ (2016) Pre-eclampsia. Lancet 387: 999–1011

Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH (2006) Cystic hygromas nuchal edema and nuchal translucency at 11–14 weeks of gestation. Obstet Gynecol 107: 678–683

Morgan S, Delbarre A, Ward P (2013) Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. Ultrasound Obstet Gynecol 41: 526–529

Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH (2011) Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 31: 135–141

Nicolaides KH (2003) Screening for chromosomal defects. Ultrasound Obstet Gynecol 21: 313–321

Nicolaides KH (2011) A model for a new pyramid of prenatal care based on the 11 to 13 weeks’ assessment. Prenat Diagn 31: 3–6

Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated twostage first-trimester screening. Ultrasound Obstet Gynecol 25: 221–226

Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Hollemon D, Cuckle H, Musci TJ, Wapner RJ (2015) Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 372: 1589–1597

Papatheodorou SI, Evangelou E, Makrydimas G, Ioannidis J (2011) First-trimester ductus venosus screening for cardiac defects: a meta-analysis. BJOG 118: 1438–1445

Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, Leung C, Saaid R, Rawashdeh H, Ogle R, Hyett J (2015) Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol 46: 419–423

Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH (2011) Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol 117: 1384–1391

Persico N, Moratalla J, Lombardi CM, Zidere V, Allan L, Nicolaides KH (2011) Fetal echocardiography at 11–13 weeks by transabdominal high-frequency ultrasound. Ultrasound Obstet Gynecol 37: 296–301

Plasencia W, Garcia R, Pereira S, Akolekar R, Nicolaides KH (2011) Criteria for screening and diagnosis of gestational diabetes mellitus in the first trimester of pregnancy. Fetal Diagn Ther 30: 108–15

Poon LC, Nicolaides KH (2014) First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn 34: 618–627

Poon LC, v Kametas NA, Pandeva I, Valencia C, Nicolaides KH (2008) Mean arterial pressure at 11 (+0) to 13 (+6) weeks in the prediction of preeclampsia.Hypertension 51: 1027–1033

Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH (2011) Firsttrimester prediction of macrosomia. Fetal Diagn Ther 29: 139–147

Prats P, Rodríguez I, Comas C, Puerto B (2014) Systematic review of screening for trisomy 21 in twin pregnancies in first trimester combining nuchal translucency and biochemical markers: a meta-analysis. Prenat Diagn 34: 1077–1083

Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E (2013) Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 41: 491–499

Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH (2017a) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med doi: 10.1056/NEJMoa1704559. [Epub ahead of print]

Rolnik DL, Wright D, Poon LC, Syngelaki A, O’Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH (2017b) ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol doi: 10.1002/uog.18816. [Epub ahead of print]

Salomon LJ, Alfirevic Z, Audibert F, Kagan KO, Paladini D, Yeo G, Raine-Fenning N, on behalf of the ISUOG Clinical Standards Committee (2014) ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound Obstet Gynecol 44: 122–123

Scazzocchio E, Figueras F (2011) Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 23: 65–71

Schmid M, Klaritsch P, Arzt W, Burkhardt T, Duba HC, Häusler M, Hafner E, Lang U, Pertl B, Speicher M, Steiner H, Tercanli S, Merz E, Heling KS, Eiben B (2015) Cell-Free DNA testing for fetal chromosomal anomalies in clinical practice: Austrian-German-Swiss recommendations for non-invasive prenatal tests (NIPT). Ultraschall Med 36: 507–510

Schulte-Vallentin M, Schindler H (1992) Non-echogenic nuchal oedema as a marker in trisomy 21 screening. Lancet 25: 8800

Senat MV, Frydman R (2007) Increased nuchal translucency with normal karyotype. Gynecol Obstet Fertil 35: 507–515

Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343–346

Snijders RJ, Sebire NJ, Nicolaides KH (1995) Maternal age and gestational agespecific risk for chromosomal defects. Fetal Diagn Ther 10: 356–367

Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH (2005) Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192: 1005–1021

Spencer K, Nicolaides KH (2003) Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 110: 276–280

Spencer K, Cowans NJ, Avgidou K, Nicolaides KH (2006) First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 28: 637–643

Spencer K, Kagan KO, Nicolaides KH (2008) Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 28: 49–52

Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH (2011) Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 31: 90–102

Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R, Nicolaides KH (2015) First-trimester screening for gestational diabetes mellitus based on maternal characteristics and history. Fetal Diagn Ther 38: 14–21

Szabo J, Gellen J (1990) Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester Lancet 336: 1133

Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 27: 1–7

Tegnander E, Williams W, Johansen OJ, Blaas HG, Eik-Nes SH (2006) Prenatal detection of heart defects in a non-selected population of 30,149 fetuses – detection rates and outcome. Ultrasound Obstet Gynecol 27: 252–265

The Fetal Medicine Foundation (2015). Nuchal translucency scan. https://fetalmedicine.org/training-n-certification/certificates-of-competence/nuchal-translucency-scan (Zugegriffen 14. Juni 2017)

Wagner P, Sonek J, Hoopmann M, Abele H, Kagan KO (2016) First-trimester screening for trisomy 18, 13, triploidy and Turner syndrome by a detailed early anomaly scan. Ultrasound Obstet Gynecol 48: 446–451

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM (2003) First and second trimester antenatal screening for Down’s syndrome: the results of the Serum Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56–104

Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH (2008) A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31: 376–383

Wright D, Bradbury I, Malone F, D’Alton M, Summers A, Huang T, Ball S, Baker A, Nix B, Aitken D, Crossley J, Cuckle H, Spencer K (2010a) Cross-trimester repeated measures testing for Down’s syndrome screening: an assessment. Health Technol Assess 14: 1–80

Wright D, Spencer K, Kagan KK, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH (2010b) First-trimester combined screening for trisomy 21 at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 36: 404–411

Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH (2011a) First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies. Fetal Diagn Ther 30: 194–202

Wright D, Syngelaki A, Staboulidou I, Cruz Jde J, Nicolaides KH (2011b) Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenat Diagn 31: 16–21

Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH (2012) A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 32: 171–178

Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH (2014) First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther 35: 118–126

Wright D, Gallo DM, Pugliese SG, Casanova C, Nicolaides KH (2016) Contingent screening for preterm preeclampsia. Ultrasound Obstet Gynecol 47: 554–559

Titel: Ersttrimesterscreening
verfasst von: Prof. Dr. med. MHBA K.-O. Kagan
PD Dr. med. H. Abele
Prof. Dr. med. M. Hoopmann
Verlag: Springer Berlin Heidelberg
Buch: Ultraschalldiagnostik in Geburtshilfe und Gynäkologie
Print ISBN: 978-3-662-53661-2

Electronic ISBN: 978-3-662-53662-9

Copyright-Jahr: 2018
DOI: https://doi.org/10.1007/978-3-662-53662-9_5

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten